title: How do palliative physicians manage venous thromboembolism?
abstract: This postal survey among 174 UK palliative physicians, aimed to assess current practice and perceived problems within the management of venous thromboembolism (VTE) in patients with advanced cancer. The questionnaire was returned by 131 out of 174 (74%) of the doctors surveyed. The most common estimated incidence of patients with VTE was 1-5%. The diagnosis of VTE is usually confirmed by further investigation and in general, outpatients are more likely to be anticoagulated than inpatients. Problems with anticoagulation include bleeding, international normalized ratio instability, appropriateness of anticoagulation, practical difficulties associated with monitoring, and recurrent VTE. Although probably less effective, 77 out of 128 (60%) of respondents use subtherapeutic regimes in order to minimize the risks. Patients with advanced malignancy and VTE are anticoagulated, if considered appropriate, by the vast majority of palliative physicians in the UK. Warfarin has been abandoned in favour of low-molecular-weight heparin (LMWH) by 26%. LMWH provides anticoagulation with no need for monitoring, has no significant drug interactions and is not affected by liver dysfunction. Theoretically, LMWH is more effective than warfarin in the secondary prevention of VTE with less risk of bleeding.
authors.affiliation: Huntershill Marie Curie Centre, Glasgow, UK.
authors.forename: M J
authors.initials: MJ
authors.lastname: Johnson
authors.forename: K
authors.initials: K
authors.lastname: Sherry
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D003657:Decision Making; D006306:Health Surveys; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications; D010166:Palliative Care; D010865:Pilot Projects; D010818:Practice Patterns, Physicians'; D011795:Surveys and Questionnaires; D013923:Thromboembolism / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; D006493:Heparin